Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Santen Pharmaceutical Co ( (JP:4536) ) is now available.
Santen Pharmaceutical Co., Ltd. has completed the disposal of 57,909 treasury shares as part of its Post-delivery Type Performance-Linked Stock Remuneration Plan. This strategic move, based on a Board of Directors resolution, aims to align the interests of directors and corporate officers with company performance, potentially impacting the company’s operational efficiency and stakeholder value.
The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1688.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen focuses on the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,511,086
Technical Sentiment Signal: Hold
Current Market Cap: Yen510.8B
For a thorough assessment of 4536 stock, go to TipRanks’ Stock Analysis page.